Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178,147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Chen B, Wang J, Pu X, Li J, Wang Q, Liu L, Xu Y, Xu L, Kong Y, Li K, Xu F, Liang S, Cardona AF, Wu L. Chen B, et al. Among authors: li j, li k. Transl Lung Cancer Res. 2022 Oct;11(10):2111-2124. doi: 10.21037/tlcr-22-697. Transl Lung Cancer Res. 2022. PMID: 36386462 Free PMC article.
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Chen B, Yao W, Li X, Lin G, Chu Q, Liu H, Du Y, Lin J, Duan H, Wang H, Xiao Z, Sun H, Liu L, Xu L, Xu Y, Xu F, Kong Y, Pu X, Li K, Wang Q, Li J, Li B, Xia Y, Wu L. Chen B, et al. Among authors: li j, li x, li k, li b. Br J Cancer. 2024 Feb;130(3):450-456. doi: 10.1038/s41416-023-02519-0. Epub 2023 Dec 18. Br J Cancer. 2024. PMID: 38110665 Clinical Trial.
178,147 results
You have reached the last available page of results. Please see the User Guide for more information.